1 |
Ren H, Fan S, Zhao Y, Guan H. The changing spectrum of antibody-mediated encephalitis in China. J Neuroimmunol. 2021; 361: 577753.
doi: 10.1016/j.jneuroim.2021.577753
|
2 |
Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018; 83(1): 166-77.
doi: 10.1002/ana.25131
pmid: 29293273
|
3 |
Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007; 61(1): 25-36.
doi: 10.1002/ana.21050
pmid: 17262855
|
4 |
Armangue T, Leypoldt F, Málaga I, Raspall-Chaure M, Marti I, Nichter C, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol. 2014; 75(2): 317-23.
doi: 10.1002/ana.24083
pmid: 24318406
|
5 |
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016; 15(4): 391-404.
doi: 10.1016/S1474-4422(15)00401-9
pmid: 26906964
|
6 |
Yuan J, Guan H, Zhou X, Niu N, Li F, Cui L, et al. Changing brain metabolism patterns in patients with ANMDARE: serial 18F-FDG PET/CT findings. Clin Nucl Med. 2016; 41(5): 366-70.
doi: 10.1097/RLU.0000000000001164
pmid: 26914566
|
7 |
Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013; 12(2): 157-65.
doi: 10.1016/S1474-4422(12)70310-1
pmid: 23290630
|
8 |
Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011; 10(1): 63-74.
doi: 10.1016/S1474-4422(10)70253-2
pmid: 21163445
|
9 |
Rodriguez A, Klein CJ, Sechi EL, Alden E, Basso MR, Pudumjee S, et al. LGI1 antibody encephalitis: acute treatment comparisons and outcome. J Neurol Neurosurg Psychiatry. 2022; 93(3): 309-15.
doi: 10.1136/jnnp-2021-327302
|
10 |
Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, et al. Use and safety of immunotherapeutic management of N-methyl-D-aspartate receptor antibody encephalitis: a meta-analysis. JAMA Neurol. 2021; 78(11): 1333-44.
doi: 10.1001/jamaneurol.2021.3188
pmid: 34542573
|
11 |
Suppiej A, Nosadini M, Zuliani L, Pelizza MF, Toldo I, Bertossi C, et al. Plasma exchange in pediatric anti-NMDAR encephalitis: a systematic review. Brain Dev. 2016; 38(7): 613-22.
doi: 10.1016/j.braindev.2016.01.009
|
12 |
Deng B, Yu H, Liu X, Yu X, Zhang X, Li X, et al. Reduced dosage rituximab in the treatment of anti-N-methyl-D-aspartate receptor encephalitis: an observation study in Chinese patients. J Neuroimmunol. 2019; 330: 81-6.
doi: S0165-5728(18)30504-6
pmid: 30851542
|
13 |
Wang BJ, Wang CJ, Zeng ZL, Yang Y, Guo SG. Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour. J Neurol Sci. 2017; 377: 127-32.
doi: 10.1016/j.jns.2017.04.007
|
14 |
Guan HZ, Xu XL, Zhu YC, Wang F, Fan S, Huang Y, et al. Clinical and immunological analysis of mycophenolate mofetil treatment in anti-leucine-rich glioma-inactivated 1 encephalitis. Chin J Neurol. 2018; 51(4): 281-7. [Article in Chinese]
|
15 |
Lee WJ, Lee ST, Shin YW, Lee HS, Shin HR, Kim DY, et al. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis. Neurotherapeutics. 2021; 18(1): 474-87.
doi: 10.1007/s13311-020-00921-7
|
16 |
Yang XZ, Zhu HD, Ren HT, Zhu YC, Peng B, Cui LY, et al. Utility and safety of intrathecal methotrexate treatment in severe anti-N-methyl-D-aspartate receptor encephalitis: a pilot study. Chin Med J (Engl). 2018; 131(2): 156-60.
|
17 |
Wang TT, Wang BJ, Zeng ZL, Li HH, Zhang FS, Ruan XY, et al. Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: an observational study. J Neuroimmunol. 2021; 354: 577527.
doi: 10.1016/j.jneuroim.2021.577527
|
18 |
van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, Schreurs MWJ, Rouhl RPW, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology. 2019; 92(19): e2185-e2196.
|
19 |
Huang XQ, Fan CQ, Wu J, Ye J, Zhan SQ, Song HQ, et al. Clinical analysis on anti-N-methyl-D-aspartate receptor encephalitis cases: Chinese experience. Int J Clin Exp Med. 2015; 8(10): 18927-35.
pmid: 26770517
|
20 |
Xu XL, Lu Q, Huang Y, Fan SY, Zhou LX, Yuan J, et al. Anti-NMDAR encephalitis: a single-center, longitudinal study in China. Neurol Neuroimmunol Neuroinflamm. 2020; 7(1): e633.
doi: 10.1212/NXI.0000000000000633
|